Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

The University of British Columbia

$72,000.00

Studies on Enzyme Mechanism and Antibiotic Resistance Strategies

EF 2023-24

Résumé
The emergence of resistant strains of bacteria presents an ever-increasing problem to human health. The ability of bacteria to rapidly mutate and develop defense mechanisms against clinically used antibiotics means that we will soon run out of effective drugs to combat bacterial infections. This proposal describes three projects that will help us to understand and possibly control the bacterial defense mechanisms that allow them to survive in a human host. The first project involves an enzyme that produces a compound called staphyloxanthin that helps the pathogenic bacteria Staphylococcus aureus survive in the human body. Our proposal describes studies that will uncover how the enzyme constructs this molecule. Such knowledge can be used to prepare molecules that will prevent the enzyme from doing its job, and thereby depriving the bacteria of their defense mechanism. Such molecules could then be used as antibiotics. The second and third projects revolve around resistance mechanisms that bacteria use to evade clinically used antibiotics. In the second project we are targeting a protein called AmpG that plays a key role in resistance to the beta-lactam antibiotics, such as penicillin. When AmpG is functional it helps to "sense" the presence of the antibiotic and leads the bacteria to produce an enzyme called a beta-lactamase that then destroys the antibiotic. This renders the antibiotic ineffective and allows the infection to spread. We plan to study the way AmpG operates and discover which molecules are most effective at getting it to signal beta-lactamase production. Interfering with AmpG function could allow the beta-lactam antibiotics to function effectively once again. In the third project, we study an enzyme called ArnD that is involved in the resistance of certain pathogenic strains of bacteria against antibiotic peptides such as polymyxin. This enzyme helps to coat the surface of the bacteria with molecules that prevent the antibiotic from binding and killing the bacteria. We plan to demonstrate the activity of ArnD for the first time and to study how it generates the "coating" compounds. This may ultimately lead to the production of inhibitors of ArnD that could prevent it from functioning, thereby unmasking the bacteria and leaving them susceptible to antibiotics.
Programme
Discovery Grants Program - Individual
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2019-05585
Name nom
Tanner, Martin
Department département
Chemistry
Organization id
2
Institution établissement
The University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2019
Award amount
72000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Organic chemistry
Research subject en
Chimie organique
Research subject fr
Chimie organique
Application title
Studies on Enzyme Mechanism and Antibiotic Resistance Strategies
Keyword
antibiotic resistance; enzyme mechanism; inhibitor design; lipid A modification; peptidoglycan recycling; prenyltransferase
Application summary
The emergence of resistant strains of bacteria presents an ever-increasing problem to human health. The ability of bacteria to rapidly mutate and develop defense mechanisms against clinically used antibiotics means that we will soon run out of effective drugs to combat bacterial infections. This proposal describes three projects that will help us to understand and possibly control the bacterial defense mechanisms that allow them to survive in a human host. The first project involves an enzyme that produces a compound called staphyloxanthin that helps the pathogenic bacteria Staphylococcus aureus survive in the human body. Our proposal describes studies that will uncover how the enzyme constructs this molecule. Such knowledge can be used to prepare molecules that will prevent the enzyme from doing its job, and thereby depriving the bacteria of their defense mechanism. Such molecules could then be used as antibiotics. The second and third projects revolve around resistance mechanisms that bacteria use to evade clinically used antibiotics. In the second project we are targeting a protein called AmpG that plays a key role in resistance to the beta-lactam antibiotics, such as penicillin. When AmpG is functional it helps to "sense" the presence of the antibiotic and leads the bacteria to produce an enzyme called a beta-lactamase that then destroys the antibiotic. This renders the antibiotic ineffective and allows the infection to spread. We plan to study the way AmpG operates and discover which molecules are most effective at getting it to signal beta-lactamase production. Interfering with AmpG function could allow the beta-lactam antibiotics to function effectively once again. In the third project, we study an enzyme called ArnD that is involved in the resistance of certain pathogenic strains of bacteria against antibiotic peptides such as polymyxin. This enzyme helps to coat the surface of the bacteria with molecules that prevent the antibiotic from binding and killing the bacteria. We plan to demonstrate the activity of ArnD for the first time and to study how it generates the "coating" compounds. This may ultimately lead to the production of inhibitors of ArnD that could prevent it from functioning, thereby unmasking the bacteria and leaving them susceptible to antibiotics.